ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240.

Ther Adv Med Oncol · 2021 · PMC8488519 · PMID 34616489

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similar to the results observed for OS, pembrolizumab plus BSC also showed a trend toward improved PFS compared with placebo plus BSC regardless of ALBI grade.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.